Moderna stock soars 658% on cancer vaccine hopes but trades far above analyst targets.

Moderna's stock has surged over 650% this year due to excitement around its personalized cancer vaccine showing promising trial results. Despite this rally, analyst price targets remain much lower than the current share price, suggesting the stock may be overvalued. The company faces risks including ongoing losses and pipeline setbacks, with key upcoming data and regulatory updates expected on November 6. Investors should weigh the potential upside against the risk of a sharp price correction if results disappoint.

Moderna's market cap stands at $90.35 billion as of Oct 15, 2026, 19:31 WIB, with a trading volume of 16,579,584 shares on Pluang. The stock price is currently $221.83, down 1.98% for the day, while buy orders dominate at 83%. Typical investors hold the stock for about 59 days, reflecting active interest despite recent volatility.